Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Collegium Poised To Re-Launch Nasal Spray As AllerNase In 2008

This article was originally published in The Pink Sheet Daily

Executive Summary

Firm is also working on reformulations of Forest/Cypress’ investigational serotonin-norepinephrine reuptake inhibitor milnacipran in Phase III development for treatment of fibromyalgia.

You may also be interested in...



Accentia Chronic Sinusitis Candidate Fails Phase III Clinical Study

Disappointing trial data for intranasal lavage formulation sends Florida firm’s stock price tumbling by more than two-thirds.

Accentia Chronic Sinusitis Candidate Fails Phase III Clinical Study

Disappointing trial data for intranasal lavage formulation sends Florida firm’s stock price tumbling by more than two-thirds.

GSK’s Veramyst To Launch By Late May

Flonase follow-on is indicated for treatment of seasonal and perennial allergic rhinitis in adults and children two years of age and older.

Topics

UsernamePublicRestriction

Register

ID1132542

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel